Valneva SE (VLA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Valneva SE (VLA) has a cash flow conversion efficiency ratio of -0.058x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.43 Million ≈ $-5.18 Million USD) by net assets (€76.70 Million ≈ $89.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Valneva SE to measure how many days the company can operate on defensive assets alone.
Valneva SE - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Valneva SE's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Valneva SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Valneva SE ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Duta Pertiwi Tbk
JK:DUTI
|
0.009x |
|
Hap Seng Plantations Holdings Bhd
KLSE:5138
|
0.001x |
|
LF Corp
KO:093050
|
0.051x |
|
Minera Alamos Inc
V:MAI
|
-7.340x |
|
Sports Toto Berhad
KLSE:1562
|
0.149x |
|
Sinopec Oilfield Service Corporation
F:YIZH
|
0.098x |
|
Tianjin Saixiang Technology Co Ltd
SHE:002337
|
0.025x |
|
Weltrend Semiconductor Inc
TW:2436
|
0.038x |
Annual Cash Flow Conversion Efficiency for Valneva SE (2005–2025)
The table below shows the annual cash flow conversion efficiency of Valneva SE from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see VLA market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €106.17 Million ≈ $124.12 Million |
€-52.89 Million ≈ $-61.84 Million |
-0.498x | -34.34% |
| 2024-12-31 | €181.25 Million ≈ $211.90 Million |
€-67.22 Million ≈ $-78.58 Million |
-0.371x | +76.54% |
| 2023-12-31 | €128.25 Million ≈ $149.93 Million |
€-202.74 Million ≈ $-237.03 Million |
-1.581x | -41.63% |
| 2022-12-31 | €219.80 Million ≈ $256.97 Million |
€-245.34 Million ≈ $-286.83 Million |
-1.116x | -347.60% |
| 2021-12-31 | €170.58 Million ≈ $199.43 Million |
€76.90 Million ≈ $89.91 Million |
0.451x | -74.66% |
| 2020-12-31 | €77.42 Million ≈ $90.51 Million |
€137.74 Million ≈ $161.03 Million |
1.779x | +4248.79% |
| 2019-12-31 | €135.15 Million ≈ $158.01 Million |
€5.53 Million ≈ $6.46 Million |
0.041x | -64.08% |
| 2018-12-31 | €143.19 Million ≈ $167.40 Million |
€16.31 Million ≈ $19.06 Million |
0.114x | -17.74% |
| 2017-12-31 | €92.67 Million ≈ $108.34 Million |
€12.83 Million ≈ $15.00 Million |
0.138x | +112.93% |
| 2016-12-31 | €100.05 Million ≈ $116.97 Million |
€6.50 Million ≈ $7.61 Million |
0.065x | +138.56% |
| 2015-12-31 | €144.34 Million ≈ $168.74 Million |
€-24.33 Million ≈ $-28.45 Million |
-0.169x | -40.39% |
| 2014-12-31 | €124.44 Million ≈ $145.49 Million |
€-14.94 Million ≈ $-17.47 Million |
-0.120x | +17.21% |
| 2013-12-31 | €144.11 Million ≈ $168.48 Million |
€-20.90 Million ≈ $-24.44 Million |
-0.145x | +71.26% |
| 2012-12-31 | €26.19 Million ≈ $30.62 Million |
€-13.22 Million ≈ $-15.46 Million |
-0.505x | -135.82% |
| 2011-12-31 | €40.45 Million ≈ $47.28 Million |
€-8.66 Million ≈ $-10.12 Million |
-0.214x | -200.52% |
| 2010-12-31 | €44.29 Million ≈ $51.78 Million |
€-3.15 Million ≈ $-3.69 Million |
-0.071x | -270.86% |
| 2009-12-31 | €22.53 Million ≈ $26.34 Million |
€939.00K ≈ $1.10 Million |
0.042x | +162.04% |
| 2008-12-31 | €27.42 Million ≈ $32.05 Million |
€-1.84 Million ≈ $-2.15 Million |
-0.067x | +45.33% |
| 2007-12-31 | €29.01 Million ≈ $33.92 Million |
€-3.56 Million ≈ $-4.17 Million |
-0.123x | +79.07% |
| 2006-12-31 | €4.66 Million ≈ $5.45 Million |
€-2.73 Million ≈ $-3.20 Million |
-0.587x | -511.87% |
| 2005-12-31 | €4.78 Million ≈ $5.59 Million |
€681.00K ≈ $796.16K |
0.143x | -- |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more